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Hyperbilirubinaemia is one of the common reasons for readmission 
of newborns in the first week after birth.[1,2] Neonatal jaundice is 
usually benign and, in most instances, does not require intervention. 
However, up to 10% of term newborns (≥37 weeks’ gestational 
age) develop severe hyperbilirubinaemia that requires treatment, 
usually phototherapy and possibly exchange blood transfusion.[3] 
Severe hyperbilirubinaemia is defined as a total serum bilirubin 
(TsB) concentration >340 µmol/L (20 mg/dL), and critical hyper­
bilirubinaemia as a TsB concentration >425 µmol/L (25 mg/dL) at 
any time during the first 28 days of life for late preterm (between 
34 and 37 weeks’ gestational age) and term newborns.[4] Failure to 
identify newborns at risk of developing severe hyperbilirubinaemia 
can lead to severe posticteric neurological consequences, including 
athetoid cerebral palsy and a variety of lifelong manifestations of 
kernicterus.[5,6]
In many settings, term newborns are discharged from hospital 
1 ­ 2 days after delivery, usually before hyperbilirubinaemia becomes 
clinically evident. Peak serum bilirubin levels usually occur on 
postnatal days 3 ­ 5, when many newborns have already been 
discharged. The inability to identify and manage at­risk infants 
prior to hospital discharge in a timely manner has been cited as 
the major root cause of adverse outcomes of hyper bilirubin aemia.[7] 
The burden of severe hyperbilirubinaemia continues to be high 
in low­ and middle­income countries (LMICs). In many LMICs, 
severe or clinically signiﬁcant neonatal hyperbilirubinaemia is 
not only a leading cause for hospital readmission in the ﬁrst 
week of life, but also constitutes an important cause of neonatal 
mortality and morbidity.[8­10] A report on the global burden of 
hyperbilirubinaemia suggests that sub­Saharan Africa and South 
Asia are the leading contributors to an estimated 1.1 million babies 
who develop severe hyperbilirubinaemia worldwide every year.[11] 
In some cases, babies have levels that could lead to subsequent brain 
damage from kernicterus.[11­15] 
Studies from African countries suggest that kernicterus is a 
leading cause of cerebral palsy.[12­14,16,17] In SA, a retrospective study 
over 5 years of exchange transfusion for hyperbilirubinaemia in 
newborns showed that 6 of 26 (23.0%) babies requiring exchange 
transfusion had signs of kernicterus.[18] Findings from various 
observational studies conducted in North America suggest that 
universal bilirubin screening in newborns before discharge reduces 
the readmission rate for jaundice and the incidence of severe 
hyperbilirubinaemia.[19­22] However, these findings have not been 
confirmed in any randomised controlled trial (RCT).[23] Furthermore, 
there is no universal consensus on the routine screening for jaundice 
in all newborns using non­invasive transcutaneous bilirubin (TcB) 
screening or TsB measurement.[24­26]
The current SA guideline on the management of jaundice in the 
newborn does not make any recommendation on universal screening 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Predischarge transcutaneous bilirubin screening reduces 
readmission rate for hyperbilirubinaemia in diverse 
South African newborns: A randomised controlled trial
C Okwundu,1 MD, MPH, DCH, PhD; V K Bhutani,2 MD, FAAP; J Smith,3 MB ChB, PhD; T M Esterhuizen,1 BSc, MSc; C Wiysonge,1,4 MD, PhD
1 Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University,  
  Cape Town, South Africa
2  Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford School of Medicine, Lucile Packard Children’s Hospital, 
Palo Alto, CA, USA 
3  Neonatology Unit, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
4 Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
Corresponding author: C Okwundu (charlesokwundu@gmail.com)
Background. In South Africa (SA), healthy term newborns are usually discharged ˂72 hours after delivery. Discharged babies remain at 
risk for severe hyperbilirubinaemia if it is not identified early. Hyperbilirubinaemia is an important cause of readmission, and also leads to 
neonatal mortality and morbidity. Use of transcutaneous bilirubin (TcB) screening before hospital discharge has been controversial.
Objectives. To test the clinical benefits of TcB screening of healthy newborns before discharge for the outcomes of readmission for jaundice 
and severe hyperbilirubinaemia in a randomised controlled trial (RCT). 
Methods. This was a RCT. We compared predischarge TcB screening with visual assessment (alone) for jaundice in apparently healthy newborns 
at a public tertiary hospital in Cape Town, SA. Patients or study participants were not involved in the study design and implementation.
Results. Of the 1 858 infants, 63% were black, 35% of mixed race and 1% white. There was a significant reduction in the rate of readmission 
for jaundice (risk ratio (RR) 0.25; 95% confidence interval (CI) 0.14 ­ 0.46; p<0.0001) and in the incidence of severe hyperbilirubinaemia 
(RR 0.27; 95% CI 0.08 ­ 0.97; p=0.05) with the use of TcB screening compared with visual inspection. 
Conclusions. Predischarge TcB screening is superior in identifying newborns at risk of severe hyperbilirubinaemia compared with visual 
inspection. We recommend that every newborn, regardless of skin pigmentation, should receive objective bilirubin screening before hospital 
discharge. Universal bilirubin screening in newborns could potentially reduce hyperbilirubinaemia­related morbidity and mortality. 
S Afr Med J 2020;110(3):249­254. https://doi.org/10.7196/SAMJ.2020.v110i3.14186
250       March 2020, Vol. 110, No. 3
RESEARCH
of all newborns with either TcB or TsB before 
hospital discharge.[27] Similarly, in other 
African countries, there are no guidelines on 
universal screening of all newborns for risk 
of hyperbilirubinaemia. In many LMICs, 
newborns are assessed for jaundice by visual 
inspection and serum bilirubin is measured 
only in newborns who appear jaundiced or 
in some cases as part of a thyroid newborn­
screening programme.[28]
In this RCT, we compared the use of a 
transcutaneous device with visual inspection 
to screen for hyperbilirubinaemia before 
hospital discharge in apparently healthy 
term and late preterm newborns (≥35 weeks’ 
gestational age).
We compared the impact of TcB screen­
ing before hospital discharge with visual 
inspection for jaundice on readmission for 
hyperbilirubinaemia, and the incidence of 
severe hyperbilirubinaemia in a SA popu­
lation of newborns.
Methods
Study design and setting 
This was a randomised, controlled, un ­
blinded trial that evaluated the effect of 
TcB screening in term newborns before 
discharge from hospital. The study was 
conducted  at the well­baby nurseries 
at Tygerberg Hospital, Cape Town, SA. 
Tygerberg Hospital is the largest tertiary 
healthcare institution in Western Cape 
Province and has 308 paediatric beds and 
~7 500 deliveries per annum. According to 
current policy, well babies born at ≥35 weeks’ 
gestation and with a birthweight ≥1 800 g are 
discharged home after 6 hours in the case of 
vaginal deliveries and 48 hours in the case of 
caesarean sections. 
Study procedures
We screened all infants at the time of 
discharge for potential eligibility into the 
study using the predetermined inclusion 
and exclusion criteria. Those who were 
≤72 hours old, with a gestational age of at 
least 35 weeks and a birthweight of at least 
1 800 g, were eligible for participation. The 
gestational age was determined by antenatal 
ultrasound scan, last menstrual period 
or postnatal foot length measured with a 
plastic Vernier’s caliper for infants whose 
mothers were unbooked and did not have 
any prenatal dating scan.[29] 
Randomisation and blinding
Infants who met all inclusion criteria were 
randomly assigned to either TcB screening 
for hyperbilirubinaemia or visual inspection 
for jaundice. A random allocation sequence 
was generated using a computer random 
sequence generator. Allocation assignments 
were recorded on sequentially numbered 
sheets of paper and placed in sealed 
opaque envelopes, maintained in a secure 
location and accessible only by the principal 
investigator (CO). The envelopes were 
opened sequentially for assignment by the 
research assistant after informed consent 
was obtained and the infants allocated to 
the group assigned in the envelope. The 
study group allocation was not blinded, 
as it is not possible to blind clinicians or 
parents to the type of screening provided due 
to the obvious nature of the intervention. 
The outcome assessors and statistician were 
blinded to the group allocation. 
Interventions
TcB screening group
In this group, we measured TcB levels once 
using the JM­105 Jaundice Meter (Dräger 
Medical, UK), a portable, handheld, non­
invasive TcB measuring device, at the time 
of enrolment.[30] An average of 3 readings 
was plotted on Bhutani’s hour­specific 
nomogram to determine the risk zone for 
hyperbilirubinaemia. Infants in this group 
were classified into the following groups: 
high risk, high intermediate risk, low 
intermediate risk and low risk (Fig. 1).[24] 
For all newborns in the high­risk zone, we 
obtained a TsB. The need for phototherapy 
was based on the TsB measurement. Infants 
who met the threshold for phototherapy 
remained in hospital for this treatment. 
Babies in the high­intermediate­risk, low­
intermediate­risk and low­risk groups were 
asked to attend follow­up at a primary 
healthcare centre closest to their home at 24, 
48 and 72 hours, respectively, after discharge 
home. We did not assess the timeliness of 
follow­up after discharge or the proportion 
of babies who went for follow­up.
Visual inspection group
Babies in this group were managed routinely 
according to the current standard of care. 
The infants were visually assessed for 
jaundice; the presence of tissue yellowness 
was assessed by blanching the skin over 
the glabella and sternum. The infants were 
evaluated by the admitting physician at the 
time of enrolment. Venous blood samples 
for TsB measurement were only collected 
in infants who were clinically jaundiced 
or in those of rhesus D­negative mothers, 
according to the hospital protocol. The need 
for phototherapy was determined based on 
the TsB result. Babies whose TsB value met 
the threshold for phototherapy according 
to the SA phototherapy guideline, were kept 
for such therapy before discharge home.[27] 
Babies who did not meet the threshold 
for phototherapy and who were not visibly 
jaundiced at the time of discharge, were 
managed routinely. The mothers were asked 
to return with their newborns for follow­
up assessments at the primary healthcare 
facility closest to their home within 2 days of 
hospital discharge.
Sample size
To the best of our knowledge, this is the 
first published study that assessed the rate 
of readmission for hyperbilirubinaemia 
in SA newborns. We assumed a baseline 
readmission rate for phototherapy of 4.8% 
from the literature and an unpublished 
local study (Ndayisaba, 2014) at Tygerberg 
Hospital on newborn readmission for 
hyperbilirubinaemia.[31­33] We estimated 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Bhutani nomogram: Bhutani VK, Johnson L, Sivieri EM. Pediatrics. 1999;103 :6 –14 
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Fig. 1. Bhutani nomogram, with permission from Dr Bhutani.[24] (TsB = total serum bilirubin.) 
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that a minimum of 1 858 participants 
would give us 80% power to detect a 50% 
reduc tion in the rate of readmission with 
the use of TcB screening at a 5% level of 
significance. 
Study outcomes
The primary endpoint was readmission 
for jaundice that required phototherapy 
or exchange transfusion. For the primary 
outcome, we compared the TcB group 
with the visual inspection group regarding 
the proportion of readmissions for hyper­
bilirubinaemia that required photo therapy 
or exchange transfusion. For every infant 
who was readmitted, we ascertained 
whether they met the threshold for either 
phototherapy or exchange transfusion 
according to the SA phototherapy guide­
line, based on the TsB result at the time of 
readmission.[27] 
The secondary endpoints were: photo­
therapy before hospital discharge, inci­
dence of severe hyperbilirubinaemia, 
critical hyperbilirubinaemia or exchange 
transfusions and duration of hospital stay 
for those who were readmitted. The rate of 
phototherapy before discharge was measured 
during hospitalisation for the birth. Other 
outcomes (readmission for phototherapy, 
incidence of severe hyperbilirubinaemia and 
duration of hospital stay) were determined 
electronically through the database and also 
by obtaining the infants’ files and electronic 
patient record transcripts from the hospital 
or primary healthcare centre where the 
baby was readmitted. We obtained all TsB 
values during the first month of life for 
newborns who were readmitted. For each 
readmission, we confirmed the name of 
the hospital or primary healthcare centre 
where the baby was readmitted, length of 
stay, treatment received (phototherapy or 
exchange transfusion) and highest TsB level 
during the readmission period.
Statistical analysis
We collected study data using paper­based 
data collection forms and then transferred 
to the REDCap (Research Electronic Data 
Capture) database. Statistical analyses were 
done with the use of Stata 14 statistical 
software (StataCorp., USA).
We performed an intention­to­treat 
analysis. Differences according to the group 
allocation for continuous variables were 
tested with the use of unpaired t­tests with 
equal variances and Wilcoxon rank­sum 
tests. The Pearson χ2 test was used to test 
for differences between the two groups for 
categorical variables. Fisher’s exact test was 
used to compare the rate of phototherapy 
before hospital discharge, readmission 
for hyperbilirubinaemia and incidence of 
severe hyperbilirubinaemia. Effect sizes were 
reported as risk ratios (RRs) with 95% confi­
dence intervals (CIs). We also adjusted for 
any plausible baseline­confounding variable 
(e.g. history of jaundice in a previous 
sibling) by performing Mantel­Haenszel 
stratification. 
Patient involvement
Patients or study participants were not 
involved in the design and implementation 
of the study.
Ethical approval
We obtained ethical approval from the Health 
Research Ethics Committee of the Faculty of 
Medicine and Health Sciences, Stellenbosch 
University (ref. no. N14/03/025). Written 
informed consent was obtained from the 
mothers for all participants before enrolment 
into the study. The trial was registered on 
clinicaltrials.gov (https://clinicaltrials.gov/
ct2/show/NCT02613676).
Results
Participant recruitment and follow-up
We enrolled a cohort of 1 858 late preterm 
and term infants born between August 2015 
and October 2016. A total of 1 910 mothers 
were approached for participation. Two 
mothers declined, and 50 were excluded 
because they did not meet our inclusion 
criteria (Fig. 2). A total of 929 infants were 
enrolled to each arm. All infants were 
screened according to the study arm to 
which they were allocated.
Participant characteristics
The baseline characteristics and demo­
graphics of enrolled infants and their 
mothers are shown in Table 1. There were 
no significant differences between the TcB 
screening arm and the visual inspection 
arm, except for the history of jaundice in 
a previous sibling, which was significantly 
higher in the TcB group. 
Outcome measures
Readmission for jaundice
There was a total of 65 (3.5%) jaundice­
related readmissions. We obtained the TsB 
results for these infants to determine if 
they met the threshold for phototherapy 
on readmission. We could not obtain the 
TsB results of 5 (3 in the visual inspection 
arm and 2 in the TcB arm) infants who 
were readmitted after discharge, and could 
not determine the appropriateness of their 
readmission. 
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Fig. 2. Participant study flow diagram.
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Thirteen of 929 (1.4%) infants were readmitted in the TcB arm 
compared with 52 of 929 (5.6%) infants in the visual inspection 
arm (RR 0.25; 95% CI 0.14 ­ 0.46; p<0.0001). (Number needed to 
treat (NNT) = 24; 95% CI 17 ­ 40.) Among all infants who were 
readmitted, there were 12 appropriate readmissions in the TcB group 
and 48 appropriate readmissions in the visual inspection group. 
As there was a randomisation imbalance in the groups regarding 
a previous baby with jaundice, adjustment was done by stratified 
analysis. The Mantel­Haenszel adjusted RR was 0.25 (95% CI 0.14 ­ 
0.46), indicating that after adjustment for having a previous baby 
with jaundice, there was still a significantly protective effect of TcB 
screening on readmission for jaundice. 
Phototherapy before discharge 
The rate of phototherapy before hospital discharge was significantly 
higher in the TcB group than in the visual inspection group. A total 
of 48 (5.2%) infants received phototherapy before hospital discharge 
compared with 18 (1.9%) in the visual inspection group (RR 2.66; 
95% CI 1.56 ­ 4.54; p=0.0002). In the TcB arm, 83 (9%) babies had 
predischarge TcB values in the high­risk zone (≥95th percentile); of 
these, 39 (47%) had TsB levels at which phototherapy was recommended 
according to the SA phototherapy guideline. A total of 131 (14%), 173 
(19%) and 542 (58%) infants had predischarge TcB measurements in 
the high­intermediate, low­intermediate and low­risk zones, respectively. 
Incidence of severe hyperbilirubinaemia
A total of 14 (0.75%) infants had severe hyperbilirubinaemia at the 
time of readmission – 3 in the TcB arm and 11 in the visual inspection 
arm. The rate of severe hyperbilirubinaemia was significantly lower 
with the use of TcB screening (RR 0.27; 95% CI 0.08 ­ 0.970; p=0.05). 
Rate of exchange transfusion
Among those who were readmitted, all infants in the TcB group 
required phototherapy and none met the threshold for exchange 
transfusion. Two infants in the visual inspection group who were 
readmitted required exchange transfusions. This difference was not 
statistically significant. 
Bilirubin-induced neurological dysfunction
There was 1 infant in the visual inspection group who had clinical 
signs that could suggest bilirubin­induced neurological dysfunction. 
The baby was born at 36 weeks’ gestational age with a birth weight of 
2 440 g, discharged home at 72 hours after delivery, and readmitted 
2 weeks later owing to prolong ed neonatal jaundice. On readmission, 
the baby was noted to have lost about 18% of the birth weight, had 
a high­pitched cry and a TsB of 459 µmol/L. No magnetic resonance 
imaging (MRI) of the brain was done and the long­term neurological 
outcome for this infant is unknown. There was no documented case 
of infants showing neurological dysfunction in the TcB arm. 
Table 1. Baseline characteristics
Variable TcB screening (N=929), n (%) Visual inspection (N=929), n (%) p-value
Gestational age (weeks), mean (SD) 38.4 (1.60) 38.3 (1.60) 0.332
<37 weeks’ gestation 123 (13.2) 144 (15.5) 0.232
≥37 weeks’ gestation 806 (86.8) 785 (84.5) 0.212
Birthweight (g), mean (SD) 3 128 (575) 3 118 (566) 0.709
IUGR 106 (12.70) 118 (11.41) 0.393
Male 485 (52.2) 480 (51.67) 0.816
Race
Black 590 (63.5) 585 (63.0) 0.320
Mixed 319 (34.3) 334 (36.0) 0.320
White 15 (1.3) 8 (0.9) 0.320
Other 3 (0.3) 2 (0.2) 0.320
Breastfeeding 870 (93.65) 893 (96.12) 0.052
Cephalohaematoma 1 (0.11) 2 (0.22) 0.056
Previous sibling with jaundice 72 (7.75) 50 (5.38) 0.039
Age at time of assessment, hours 31.1 31.9 0.283
Mode of delivery
NVD 492 (52.96) 510 (54.90) 0.287
Caesarean section 425 (45.75) 413 (44.46) 0.287
Vacuum 12 (1.29) 6 (0.65) 0.287
Mother’s Rh status
Negative 16 (1.72) 14 (1.51) 0.927
Positive 871 (93.76) 874 (94.08) 0.927
Unknown 42 (4.52) 41 (4.41) 0.927
Mother’s blood group
A 31 (3.34) 25 (2.69) 0.666
AB 7 (0.75) 3 (0.32) 0.666
B 16 (1.72) 16 (1.72) 0.666
O 37 (3.98) 35 (3.77) 0.666
TcB = transcutaneous bilirubin; SD = standard deviation; IUGR = intrauterine growth restriction (determined using the World Health Organization international growth standards for 
children ˂5 years); NVD = normal vertex delivery; Rh = rhesus.
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TsB before discharge
A total of 87 (9%) infants required TsB before discharge in the TcB 
group compared with 70 (7.5%) in the visual inspection group 
(RR 1.24; 95% CI 0.91 ­ 1.68; p=0.156). The difference was not statis­
ti cally significant.
Duration of hospital stay
The median duration of hospital stay during the readmission period 
was similar in both groups. Median duration of hospital stay in the 
visual inspection group was 3 (interquartile range (IQR) 2 ­ 4) days 
compared with 3 (IQR 2 ­ 3) days in the TcB group. The Wilcoxon 
rank­sum (Mann­Whitney) test did not demonstrate any statistically 
significant difference between arms (p=0.216).
Discussion
In this RCT involving indigenous South African newborns recruited 
from a tertiary hospital in SA, we provide evidence for the effect 
of predischarge TcB screening on readmission for jaundice and 
incidence of severe hyperbilirubinaemia. To our knowledge, this 
RCT is the first to evaluate the impact of TcB screening in a 
South African population of newborns. We demonstrated that 
TcB screening for hyperbilirubinaemia was superior in identifying 
apparently healthy newborns requiring phototherapy before hospital 
discharge compared with visual inspection. Earlier identification of 
hyperbilirubinaemia combined with treatment with phototherapy 
during the initial hospitalisation for the birth led to a reduction in 
readmission rate with the use of TcB screening.
Unexpected readmission of a newborn after discharge is an 
indicator of inadequate assessment of the newborn’s readiness for 
discharge. For our study, we selected the readmission rate as a 
primary outcome. Although this index is often viewed from the 
perspective of healthcare cost, epidemiological burden and societal 
burden of trust between healthcare provider and the family, it can 
have a direct personal disruption in the maternal and newborn 
experience.[34­37]
In 2004, the American Academy of Pediatrics (AAP) recommended 
a patient­friendly systems approach, i.e. that every newborn should 
be assessed for the risk of developing severe hyperbilirubinaemia by 
using predischarge TsB or TcB measurements, a policy also endorsed 
by the Canadian Paediatric Society (CPS).[4,24] After implementation 
of the AAP and CPS guidelines, many studies in the USA and 
Canada have demonstrated that universal TcB or TsB reduced 
jaundice readmissions and led to a reduction in the incidence of 
severe hyperbilirubinaemia.[20­22,32,38,39] Our study not only validates 
the finding from these studies, but also provides evidence that 
earlier identification of hyperbilirubinaemia with TcB screening 
and treatment with phototherapy is associated with a reduction 
in hospital readmission rates for hyperbilirubinaemia and in the 
incidence of severe hyperbilirubinaemia in an indigenous population 
of South African newborns. 
Other studies from LMICs have evaluated the correlation of 
TcB compared with TsB measurement in newborns with different 
skin pigmentation. These have shown a good correlation, and that 
implementation of TcB screening is feasible in LMICs.[40­47] However, 
because of varying access to healthcare and differential risk in 
the polycultural community of LMICs, there are limited – if any – 
national policy outcome studies. Therefore, we could not identify any 
studies from LMICs that evaluated the impact of TcB screening on 
readmission rate or incidence of severe hyperbilirubinaemia.
Study limitations
Our study has some important limitations. It did not evaluate the 
impact of TcB screening on reducing the incidence of kernicterus, 
which would require a very large study and longer follow­up period. 
In our study, only 1 infant in the visual inspection arm had a clinical 
sign of probable kernicterus. Blood group typing and the direct 
Coombs’ test for blood group incompatibility were not routinely 
done on all newborns. Therefore, we could not assess whether there 
was any difference in the rate of blood group incompatibility between 
the two study arms. It was difficult to determine if the highest TsB 
measurement was recorded prior to phototherapy initiation. In 
some facilities where babies were readmitted, phototherapy was 
initiated before a blood sample for TsB was collected. Therefore, 
the incidence of severe hyperbilirubinaemia in the study population 
could be higher than that reported. Blood for TsB measurement was 
ordered at the discretion of the admitting physician. The outcome 
would possibly have been different if we limited blood sampling 
only to infants whose TcB value was >95th percentile for their age. 
This study was conducted in a tertiary facility where some mothers 
were kept longer because of other medical reasons and consequently 
the babies were also kept longer together with their mothers. This 
increased the length of stay for some babies, which could lead to 
a reduction in readmission because of delayed discharge from the 
initial hospitalisation for the birth. Therefore, the readmission rates 
reported are likely to be higher in the primary healthcare setting 
in SA, where mothers without any complications after delivery are 
typically discharged within 12 hours of delivery. However, despite 
these limitations, we are confident about the findings, because of the 
unique design of the study compared with other non­randomised 
studies that have evaluated similar outcomes.[20­22,32,38,39] We have 
provided evidence from a randomised controlled study. We used a 
proper method of randomisation and allocation concealment, with 
sealed opaque envelopes. Even though this method of concealment of 
allocation is prone to deliberate tampering, the investigators ensured 
that the envelopes were only opened at the time of enrolment. 
The study participants were similar with regard to the baseline 
characteristics. Although the study personnel and participants were 
not blinded to the treatment allocation, the outcome assessors 
and statistician were blinded. Therefore, we are confident that the 
reduction in hospital readmission rate and in the incidence of severe 
hyperbilirubinaemia was as a result of the TcB screening strategy in 
the treatment group.
Conclusions 
TcB screening with risk stratification using the Bhutani nomogram 
in newborn infants at risk of severe hyperbilirubinaemia can help 
to reduce readmissions for jaundice and the incidence of severe 
hyperbilirubinaemia. Our study further confirms that visual 
inspection for jaundice is not reliable to assess the presence or absence 
of hyperbilirubinaemia in newborns. Universal TcB screening in 
all newborns before hospital discharge in SA and other African 
countries will be an important step towards reducing the burden 
and consequences of severe hyperbilirubinaemia. However, the high 
cost of the current TcB devices could be a barrier to implementation 
of universal TcB screening in many LMICs. Currently, a TcB device 
could cost between ZAR50 000 and ZAR100 000. However, the use 
of TcB to screen for hyperbilirubinaemia in newborns has been 
shown to be good value for money.[48] Therefore, nationally driven 
public­private solutions are warranted, such that healthcare during 
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the first week after a normal pregnancy is equitable. Industry and 
TcB manufacturers now have the moral responsibility to make 
over­priced transcutaneous devices safe, affordable and accessible. 
Reductions in the cost of readmission, the cost of more intensive 
treatment, and the family’s integrity are real and need to be realised 
for all newborns worldwide.
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